Table 1.
Dysregulation and mechanism of miR-24 in different types of human cancer.
| Cancer | Alteration | Mechanistically | References |
|---|---|---|---|
| NPC | Down-regulated | Enhance radiosensitivity by targeting SP1, Jab1/CSN5, FSCN1 | (9, 24–26) |
| CRC | Down-regulated | Decrease cell proliferation, migration | (10, 20) |
| LSCC | Down-regulated | Inhibit cell growth and enhance radiosensitivity by targeting XIAP | (11) |
| PC | Down-regulated | Increase cell apoptosis by targeting p27, p16, FSCN1 | (27, 28) |
| LA | Down-regulated | Suppress cancer progression by targeting FGFR3, SOX18 | (29, 30) |
| BLC | Down-regulated | Inhibit cell proliferation and metastasis by targeting CARMA3 | (31) |
| GC | Down-regulated | Restrain cancer progression by downregulating RegIV | (32, 33) |
| PDA | Down-regulated | Inhibit cell proliferation by targeting LAMB3 | (34) |
| RB | Down-regulated | Suppress cancer progression by targeting c-Myc | (35) |
| EC | Down-regulated | Suppress cell growth by targeting FERMT1 | (36) |
| NSCLC | Up-regulated | Promote cancer progression | (6) |
| HCC | Up-regulated | Increase cell metastasis and invasion by targeting p53 | (7, 15, 37) |
| BC | Up-regulated | Inhibit cell apoptosis by targeting Bim, ING5, p27Kip1, caspase-3 | (8, 18, 38–41) |
| TSCC | Up-regulated | Promote cell growth, migration and invasion by targeting PTEN, FBXW7 | (42, 43) |
| LC | Up-regulated | Promote cell growth and metastasis by targeting SOX7, menin | (44, 45) |
| BLC | Up-regulated | Promote cancer progression by inhibiting DEDD | (46) |
| GC | Up-regulated | Promote cell growth, migration; inhibit apoptosis by targeting BCL2L11 | (47) |
| AL | Up-regulated | Promote cancer progression | (48) |
| HL | Up-regulated | Protect Hodgkin and Reed-Sternberg cells from apoptosis | (49) |
| OSCC | Up-regulated | Maintain cell proliferation through targeting PER1 | (50) |
| LSCC | Up-regulated | Mediate the associations of titanium with chromosome damage and cancer | (51) |
| PAC | Up-regulated | Promote cell migration and invasion by targeting FZD5, TMEM92 | (52) |
NPC, nasopharyngeal carcinoma; CRC, colorectal cancer; LSCC, laryngeal squamous cell carcinoma; PC, prostate cancer; LA, lung adenocarcinoma; BLC, bladder cancer; GC, gastric cancer; RB, retinoblastoma; PDA, pancreatic ductal adenocarcinoma; EC, esophageal cancer; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; BC, breast cancer; TSCC, tongue squamous cell carcinoma; LC, lung cancer; AL, acute leukemia; HL, Hodgkin Lymphoma; OSCC, oral squamous cell carcinoma; LSCC, lung squamous cell carcinoma; PAC, pancreatic cancer.